USANA Health Sciences (USNA) News Today

USANA Health Sciences, Inc. (NYSE: USNA) shares have increased in the latest trading session, but the broader news flow remains sharply negative following the company’s disappointing second-quarter results and reduced outlook.

• Positive Sentiment: Sidoti raised its EPS forecasts for Q3 2026 to $0.11 from $0.09, Q1 2027 to $0.34 from $0.31, and Q2 2027 to $0.46 from $0.43. These upward revisions may be supporting a short-term rebound by suggesting analysts see potential earnings improvement beyond the current quarter. MarketBeat USANA analyst estimates
• Neutral Sentiment: Analyst sentiment has become mixed: Sidoti raised select forward estimates, while other analysts lowered near-term expectations. Investors may view the conflicting forecasts as a sign of uncertainty regarding USANA’s recovery.
• Negative Sentiment: USANA’s second-quarter earnings were far below expectations, and revenue also missed forecasts. The company now expects a full-year loss, a major deterioration from earlier expectations and the primary reason the stock has been under pressure this week. Why USANA Health Sciences Stock Plummeted This Week
• Negative Sentiment: An analyst reduced the estimate for USANA’s third-quarter EPS, indicating weaker expected profitability following the earnings miss. Q3 EPS Estimate for USANA Health Sciences Cut by Analyst
• Negative Sentiment: Zacks Research downgraded USANA from “hold” to “strong sell,” adding to the bearish analyst sentiment. Wall Street Zen also lowered its rating, reinforcing concerns about the company’s earnings outlook. Zacks Research